MedTrace Logo

T Cell Vaccination in Patients With Progressive Multiple Sclerosis

NCT01448252 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-10-07

No results posted yet for this study

Summary

This is a double blind phase I-II clinical trial with multiple autologous T cell vaccinations using T cell lines reactive to 9 different myelin peptides of MBP, MOG and PLP, in patients with relapsing progressive Multiple Sclerosis.

Conditions

Interventions

BIOLOGICAL

multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)

multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180

BIOLOGICAL

T cell vaccination

Multiple injections of autologous T cell lines reactive to 9 myelin peptides.

Sponsors & Collaborators

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Dimitrios Karussis, Prof. · Hadassah Medical Organizatin

  • Rivka Abulafia-Lapid, PhD · Hadassah Medical Organization

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2008-09-30
Completion
2009-03-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01448252 on ClinicalTrials.gov